Moolec Science (MLEC) Return on Capital Employed (2023 - 2024)
Moolec Science (MLEC) reported Return on Capital Employed of 35.84% for Q4 2024, up 3406.0% on a YoY basis from 1.02% in Q1 2024, and down 1853.43% sequentially from 1.83% in Q3 2024.
Moolec Science (MLEC) Return on Capital Employed (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Return on Capital Employed data on file, last reported at 35.84% in Q4 2024.
- For the quarter ending Q4 2024, Return on Capital Employed rose 3406.0% year-over-year to 35.84%; the trailing twelve-month figure through Dec 2024 stood at 35.84% (up 3406.0% YoY), and the FY2024 full-year result was 15.19%, up 236284.0% from the prior year.
- Return on Capital Employed declined to 35.84% in Q4 2024, from 1.83% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1.83% in Q3 2024 to a low of 752.81% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -35.84% |
| Sep 30, 2024 | -1.83% |
| Jun 30, 2024 | -14.95% |
| Mar 31, 2024 | -64.41% |
| Dec 31, 2023 | -69.90% |
| Sep 30, 2023 | -76.25% |
| Jun 30, 2023 | -752.81% |
| Mar 31, 2023 | -31.95% |